Related references
Note: Only part of the references are listed.The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses
Arne Ring et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin
David W. Boulton et al.
CLINICAL PHARMACOKINETICS (2011)
Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment
M. Nowicki et al.
DIABETES OBESITY & METABOLISM (2011)
Recognition, Pathogenesis, and Treatment of Different Stages of Nephropathy in Patients With Type 2 Diabetes Mellitus
George L. Bakris
MAYO CLINIC PROCEEDINGS (2011)
Pharmacokinetics of dipeptidylpeptidase-4 inhibitors
A. J. Scheen
DIABETES OBESITY & METABOLISM (2010)
The Metabolism and Disposition of the Oral Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, in Humans
Stefan Blech et al.
DRUG METABOLISM AND DISPOSITION (2010)
Impact of Target-Mediated Drug Disposition on Linagliptin Pharmacokinetics and DPP-4 Inhibition in Type 2 Diabetic Patients
Silke Retlich et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes
Morali Sharma et al.
Therapeutics and Clinical Risk Management (2010)
Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients
T. Heise et al.
DIABETES OBESITY & METABOLISM (2009)
Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans
Holger Fuchs et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2009)
Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers
S. Huettner et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor
Arthur J. Bergman et al.
DIABETES CARE (2007)
Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans
Stella H. Vincent et al.
DRUG METABOLISM AND DISPOSITION (2007)
Share Paper
